These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38479497)
61. Preservation of renal function in cardiac surgery patients with low cardiac output syndrome: levosimendan vs beta agonists. Guerrero Orriach JL; Navarro Arce I; Hernandez Rodriguez P; Raigón Ponferrada A; Malo Manso A; Ramirez Aliaga M; Ramirez Fernandez A; Escalona Belmonte JJ; Bellido Estevez I; Gomez Luque A; Barrera Serrano R; Toledo Medina CS; Rubio Navarro M; Cruz Mañas J BMC Anesthesiol; 2019 Nov; 19(1):212. PubMed ID: 31735161 [TBL] [Abstract][Full Text] [Related]
62. Levosimendan in cardiac amyloidosis: Unveiling promising paths. Faggiano A; Carugo S; Sinagra G; Merlo M Int J Cardiol; 2024 Jul; 406():131994. PubMed ID: 38575001 [No Abstract] [Full Text] [Related]
63. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study. Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055 [TBL] [Abstract][Full Text] [Related]
64. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Kivikko M; Lehtonen L Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064 [TBL] [Abstract][Full Text] [Related]
65. Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function. John B; Babu M; Shaji S; Abraham S; Abdullakutty J Indian Heart J; 2021; 73(3):372-375. PubMed ID: 34154760 [TBL] [Abstract][Full Text] [Related]
66. Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials. Long YX; Cui DY; Kuang X; Hu Y; Hu S; Wang CP; Liu ZZ Expert Opin Drug Saf; 2021 Nov; 20(11):1411-1420. PubMed ID: 34214005 [TBL] [Abstract][Full Text] [Related]
67. Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan. Qarawani D; Cohen A; Nahir M; Hasin Y Int J Cardiol; 2013 Sep; 168(1):237-42. PubMed ID: 23063476 [TBL] [Abstract][Full Text] [Related]
68. Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. d'Humières T; Fard D; Damy T; Roubille F; Galat A; Doan HL; Oliver L; Dubois-Randé JL; Squara P; Lim P; Ternacle J Arch Cardiovasc Dis; 2018 Oct; 111(10):582-590. PubMed ID: 29709420 [TBL] [Abstract][Full Text] [Related]
69. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177 [TBL] [Abstract][Full Text] [Related]
70. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure. Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501 [TBL] [Abstract][Full Text] [Related]